Compounds > plerixafor
Page last updated: 2024-08-24

plerixafor and ER-Negative PR-Negative HER2-Negative Breast Cancer

plerixafor has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Chen, XL; Du, CW; Guo, JF; Wu, JF; Wu, NQ; Xie, XF; Zhang, GL1
Du, CW; Guo, QM; Peng, X; Wang, WH; Wu, JF; Wu, QY; Xie, LH; Zhang, GJ; Zhang, GL; Zhou, KX1
Cui, Y; Lin, J; Pan, H; Peng, Z; Ren, X; Zhang, G1
Durmaz, H; Lahann, J; Luker, GD; Luker, KE; Misra, AC1
Bieche, I; Kieffer, Y; Lefort, S; Marangoni, E; Mechta-Grigoriou, F; Sirven, P; Thuleau, A; Vincent-Salomon, A1

Other Studies

5 other study(ies) available for plerixafor and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Cancer letters, 2022, 12-28, Volume: 551

    Topics: Cell Line, Tumor; DNA Damage; Humans; Phthalazines; Poly (ADP-Ribose) Polymerase-1; Receptors, CXCR4; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2022
CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
    Cancer letters, 2018, 04-01, Volume: 418

    Topics: Animals; Apoptosis; Benzylamines; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cyclams; Female; Heterocyclic Compounds; Humans; Mice, Nude; Radiation, Ionizing; Receptors, CXCR4; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
    Cancer science, 2018, Volume: 109, Issue:12

    Topics: Animals; Benzylamines; Cell Line, Tumor; Cell Movement; Cyclams; Female; Forkhead Transcription Factors; Heterocyclic Compounds; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Receptors, CXCR4; Transcriptional Activation; Triple Negative Breast Neoplasms; Zebrafish

2018
CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.
    Biomacromolecules, 2015, Aug-10, Volume: 16, Issue:8

    Topics: Benzylamines; Cell Line, Tumor; Cyclams; Drug Delivery Systems; Female; Heterocyclic Compounds; Humans; Nanoparticles; Receptors, CXCR4; Triple Negative Breast Neoplasms

2015
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
    Oncogene, 2017, 03-02, Volume: 36, Issue:9

    Topics: Animals; Anti-HIV Agents; Apoptosis; Benzylamines; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Cyclams; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptides; Receptor, ErbB-2; Receptors, CXCR4; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017